BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rothenburger T, McLaughlin KM, Herold T, Schneider C, Oellerich T, Rothweiler F, Feber A, Fenton TR, Wass MN, Keppler OT, Michaelis M, Cinatl J Jr. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine. Commun Biol 2020;3:324. [PMID: 32581304 DOI: 10.1038/s42003-020-1052-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen Z, Hu J, Ying S, Xu A. Dual roles of SAMHD1 in tumor development and chemoresistance to anticancer drugs. Oncol Lett 2021;21:451. [PMID: 33907561 DOI: 10.3892/ol.2021.12712] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zheng J, Zhang T, Guo W, Zhou C, Cui X, Gao L, Cai C, Xu Y. Integrative Analysis of Multi-Omics Identified the Prognostic Biomarkers in Acute Myelogenous Leukemia. Front Oncol 2020;10:591937. [PMID: 33363022 DOI: 10.3389/fonc.2020.591937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ju J, Han W, Shi C. Long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 gene (PVT1) modulates the proliferation and apoptosis of acute lymphoblastic leukemia cells by sponging miR-486-5p. Bioengineered 2022;13:4587-97. [DOI: 10.1080/21655979.2022.2031405] [Reference Citation Analysis]
4 Schott K, Majer C, Bulashevska A, Childs L, Schmidt MHH, Rajalingam K, Munder M, König R. SAMHD1 in cancer: curse or cure? J Mol Med (Berl) 2021. [PMID: 34480199 DOI: 10.1007/s00109-021-02131-w] [Reference Citation Analysis]
5 Rindiarti A, Okamoto Y, Nakagawa S, Hirose J, Kodama Y, Nishikawa T, Kawano Y. Changes in intracellular activation-related gene expression and induction of Akt contribute to acquired resistance toward nelarabine in CCRF-CEM cell line. Leuk Lymphoma 2022;:1-12. [PMID: 35080473 DOI: 10.1080/10428194.2021.1992617] [Reference Citation Analysis]
6 Pons M, Zeyn Y, Zahn S, Mahendrarajah N, Page BDG, Gunning PT, Moriggl R, Brenner W, Butter F, Krämer OH. Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers (Basel) 2021;13:3464. [PMID: 34298678 DOI: 10.3390/cancers13143464] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rothenburger T, Thomas D, Schreiber Y, Wratil PR, Pflantz T, Knecht K, Digianantonio K, Temple J, Schneider C, Baldauf HM, McLaughlin KM, Rothweiler F, Bilen B, Farmand S, Bojkova D, Costa R, Ferreirós N, Geisslinger G, Oellerich T, Xiong Y, Keppler OT, Wass MN, Michaelis M, Cinatl J Jr. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells. J Exp Clin Cancer Res 2021;40:317. [PMID: 34641952 DOI: 10.1186/s13046-021-02093-4] [Reference Citation Analysis]
8 Simioni C, Conti I, Varano G, Brenna C, Costanzi E, Neri LM. The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies. Front Oncol 2021;11:673506. [PMID: 34026651 DOI: 10.3389/fonc.2021.673506] [Reference Citation Analysis]
9 Pocock R, Farah N, Richardson SE, Mansour MR. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia. Br J Haematol 2021;194:28-43. [PMID: 33942287 DOI: 10.1111/bjh.17310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]